Education
About Us
Working with TipRanks
Follow Us
Modus Therapeutics Holding AB (DE:99Z)
FRANKFURT:99Z
99Z Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.09 - €0.19
Previous CloseN/A
Volume0.00
Average Volume (3M)333.00
Market Cap
€4.66M
Enterprise Value€49.35M
Total Cash (Recent Filing)€4.38M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.61
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding35,938,900
10 Day Avg. Volume0
30 Day Avg. Volume333
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)25.14
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
99Z FAQ
What was Modus Therapeutics Holding AB’s price range in the past 12 months?
Modus Therapeutics Holding AB lowest stock price was €0.09 and its highest was €0.19 in the past 12 months.
What is Modus Therapeutics Holding AB’s market cap?
Modus Therapeutics Holding AB’s market cap is €4.66M.
When is Modus Therapeutics Holding AB’s upcoming earnings report date?
Modus Therapeutics Holding AB’s upcoming earnings report date is Aug 27, 2025 which is in 82 days.
How were Modus Therapeutics Holding AB’s earnings last quarter?
Modus Therapeutics Holding AB released its earnings results on May 14, 2025. The company reported -€0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.007.
Is Modus Therapeutics Holding AB overvalued?
According to Wall Street analysts Modus Therapeutics Holding AB’s price is currently Overvalued.
Does Modus Therapeutics Holding AB pay dividends?
Modus Therapeutics Holding AB does not currently pay dividends.
What is Modus Therapeutics Holding AB’s EPS estimate?
Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modus Therapeutics Holding AB have?
Modus Therapeutics Holding AB has 35,938,900 shares outstanding.
What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?
Modus Therapeutics Holding AB reported an EPS of -€0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.333%.
Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?
Currently, no hedge funds are holding shares in DE:99Z
Company Description
Modus Therapeutics Holding AB
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a polysaccharide to treat patients with sepsis and septic shock, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
Technical Analysis
Stayble Therapeutics AB
―
ExpreS2ion Biotech Holding AB
―
Spago Nanomedical AB
―
CombiGene AB
―
Sprint Bioscience AB
―